Patient preferences for Interferon-beta in Iran: A discrete choice experiment

Area of Science:

• Neurology
• Pharmacoeconomics
• Health Policy

Background:

• Multiple sclerosis (MS) is a chronic, progressive central nervous system disease common in young adults.
• Interferon-beta (IFN-β) is a primary therapy to slow MS progression, with various formulations available.

Purpose of the Study:

• To identify patient preferences for specific attributes of interferon-beta (IFN-β) treatments for multiple sclerosis (MS).
• To inform healthcare policy and pharmaceutical strategies by understanding patient-valued treatment characteristics.

Main Methods:

• A discrete choice experiment (DCE) was employed.
• 358 MS patients in Isfahan, Iran, completed questionnaires presenting treatment choice scenarios.
• Logit models were used to analyze patient preferences and attribute utility.

Main Results:

• Treatment efficacy was the most significant factor influencing patient utility for IFN-β.
• Reduced side effects and ease of injection were the next most important attributes.
• Patient preferences highlight key areas for optimizing MS treatment selection.

Conclusions:

• Aligning IFN-β treatments with patient-prioritized attributes, particularly efficacy, can enhance medication adherence.
• Findings provide valuable insights for pharmaceutical manufacturers, regulatory bodies, and healthcare providers in Iran and potentially beyond.
• Understanding patient preferences is crucial for effective multiple sclerosis management and resource allocation.